BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by ClariVest Asset Management LLC

ClariVest Asset Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,600 shares of the biotechnology company’s stock after selling 4,600 shares during the quarter. ClariVest Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $260,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of BCRX. Janney Montgomery Scott LLC raised its holdings in BioCryst Pharmaceuticals by 13.3% during the second quarter. Janney Montgomery Scott LLC now owns 25,550 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 3,000 shares in the last quarter. American International Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 3.6% during the 2nd quarter. American International Group Inc. now owns 94,339 shares of the biotechnology company’s stock worth $450,000 after purchasing an additional 3,300 shares in the last quarter. Point72 Hong Kong Ltd increased its stake in shares of BioCryst Pharmaceuticals by 160.5% during the 2nd quarter. Point72 Hong Kong Ltd now owns 7,184 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 4,426 shares in the last quarter. Dowling & Yahnke LLC increased its stake in shares of BioCryst Pharmaceuticals by 45.5% during the 3rd quarter. Dowling & Yahnke LLC now owns 16,000 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 5,000 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in BioCryst Pharmaceuticals by 2.3% in the 2nd quarter. California State Teachers Retirement System now owns 234,035 shares of the biotechnology company’s stock worth $1,115,000 after acquiring an additional 5,181 shares during the period. 74.35% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BCRX stock opened at $4.33 on Friday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $6.29. The stock has a market cap of $764.53 million, a PE ratio of -5.70 and a beta of 2.90. The business’s fifty day moving average is $3.90 and its 200-day moving average is $4.28. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.40 and a current ratio of 1.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Thursday, November 5th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 328.70% and a negative net margin of 233.45%. Equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.97 earnings per share for the current year.

A number of equities analysts have weighed in on BCRX shares. Bank of America reiterated a “buy” rating and issued a $6.00 price target on shares of BioCryst Pharmaceuticals in a report on Sunday, October 4th. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, September 29th. They issued an “overweight” rating on the stock. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 7th. Royal Bank of Canada reissued a “hold” rating and issued a $4.50 price target on shares of BioCryst Pharmaceuticals in a report on Friday, August 28th. Finally, BidaskClub downgraded BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 25th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. BioCryst Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.00.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: What sectors are represented in the Hang Seng index?

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.